Literature DB >> 3135974

Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate.

A Y Elzouki1, O P Jaiswal.   

Abstract

A prospective study was performed to evaluate the effect of long-term small-dose prednisone therapy in frequently relapsing nephrotic syndrome (NS); 37 patients were included, with a relapse rate 4.6/patient/year (range, 3-8) (mean age, 6.7 years; range, 2-15 years). Prednisone was started 2 mg/kg/day once remission was induced. Prednisone was progressively reduced over weeks until 10 mg/day was reached, and then the daily dose was changed to 10 mg on alternate days. On follow-up (mean, 25.4 months; range, 10-58 months), only five had subsequent relapses and their relapse rate decreased significantly to 1.2/patient/year (p less than 0.05). Forty-six episodes of infection were associated with exacerbation of NS; 41 of these excerbations remitted spontaneously without an increase in the dose of prednisone. Serial height and weight measurements revealed evidence of improved height velocity and obesity persisted in only two of 13 initially obese children.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135974     DOI: 10.1177/000992288802700807

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  17 in total

1.  Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.

Authors:  Akio Nakamura; Ryo Niimi; Kumiko Kurosaki; Yukishige Yanagawa
Journal:  Clin Exp Nephrol       Date:  2010-07-17       Impact factor: 2.801

2.  Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.

Authors:  Bethany J Foster; Justine Shults; Babette S Zemel; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

3.  Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.

Authors:  Menka Yadav; Aditi Sinha; Priyanka Khandelwal; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2018-09-07       Impact factor: 3.714

Review 4.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.

Authors:  Rebecca M Lombel; Debbie S Gipson; Elisabeth M Hodson
Journal:  Pediatr Nephrol       Date:  2012-10-03       Impact factor: 3.714

5.  Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases.

Authors:  Natalie J Shiff; Rollin Brant; Jaime Guzman; David A Cabral; Adam M Huber; Paivimm Miettunen; Johannes Roth; Rosie Scuccimarri; Nathalie Alos; Stephanie A Atkinson; Jean Paul Collet; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Bianca Lang; Maggie Larche; Claire Leblanc; Celia Rodd; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Frank Rauch; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

6.  Evaluation of chlorambucil therapy in steroid-dependent and cyclophosphamide-resistant children with nephrosis.

Authors:  A Y Elzouki; O P Jaiswal
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

7.  Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome.

Authors:  R N Srivastava; A S Vasudev; A Bagga; K R Sunderam
Journal:  Pediatr Nephrol       Date:  1992-05       Impact factor: 3.714

Review 8.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

9.  Long-term linear growth of children with severe steroid-responsive nephrotic syndrome.

Authors:  Francesco Emma; Antonella Sesto; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2003-06-13       Impact factor: 3.714

10.  Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.

Authors:  Mai Sato; Shuichi Ito; Masao Ogura; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2014-03-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.